Age | ||
 Median | 77 | Range [63–81] |
Comorbidities | ||
 None | 4 (30.7%) |  |
 1 Comorbidity | 4 (30.7%) |  |
  > 1 Comorbidities | 5 (38.6%) |  |
Anticoagulants | ||
 Yes | 5 (38.6%) |  |
 No | 8 (61.4%) |  |
Alpha blockers | ||
 Yes | 5 (38.6%) |  |
 No | 8 (61.4%) |  |
IPSS | ||
 Median | 8 | Range [2–14] |
Prostate volume (mL) | ||
 Median | 35.5 | Range [24–80] |
NCCN risk group | ||
 Intermediate unfavorable | 7 (69.2%) |  |
 High | 3 (23.1%) |  |
 Very High | 1 (7.7%) |  |
Gleason score | ||
 7 (4 + 3) | 9 (69.2%) |  |
 8 (4 + 4) | 2 (15.4%) |  |
 9 (4 + 5) | 1 (7.7%) |  |
 10 (5 + 5) | 1 (7.7%) |  |
ISUP grading group | ||
 3 | 9 (69.2%) |  |
 4 | 2 (15.4%) |  |
 5 | 2 (15.4%) |  |
Clinical stage | ||
 T2a | 4 (30.8%) |  |
 T2b | 2 (15.4%) |  |
 T2c | 6 (46.1%) |  |
 T3a | 1 (7.7%) |  |
PSA level (mg/mL) | ||
 Median | 9.78 | Range [4.99–20] |
  < 10 | 8 (61.4%) |  |
 10–20 | 5 (38.6%) |  |
Radiation therapy prescribed and delivered | ||
 40 Gy in 5 fractions | 4 (30.8%) |  |
 38 Gy in 4 fractions | 9 (69.2%) |  |
CTV (cc) | ||
 Median | 47.05 | Range [32.06–96.71] |
PTV (cc) | ||
 Median | 66.60 | Range [48.89–128.53] |
PTV (D95) | ||
 Median | 96% | Range [95–97%] |